Whetstone Capital Advisors LLC Has $13.06 Million Position in OptimizeRx Corp. $OPRX

Key Points

• Whetstone Capital Advisors LLC increased its holdings in OptimizeRx Corp. by 11.7% in Q1, now owning 1,508,303 shares valued at approximately $13.06 million.
• Several institutional investors, including JPMorgan Chase & Co., have significantly increased their stakes in OptimizeRx, reflecting growing interest; 76.47% of the stock is held by institutional investors.
• OptimizeRx has received multiple buy ratings from brokerages, with a consensus target price of $11.81 and an overall consensus rating of "Moderate Buy."

Whetstone Capital Advisors LLC increased its holdings in OptimizeRx Corp. (NASDAQ:OPRX - Free Report) by 11.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,508,303 shares of the company's stock after buying an additional 157,880 shares during the quarter. OptimizeRx comprises 5.8% of Whetstone Capital Advisors LLC's portfolio, making the stock its 6th largest holding. Whetstone Capital Advisors LLC owned about 8.16% of OptimizeRx worth $13,062,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in OPRX. JPMorgan Chase & Co. grew its holdings in OptimizeRx by 670.3% in the 4th quarter. JPMorgan Chase & Co. now owns 59,952 shares of the company's stock worth $291,000 after buying an additional 52,169 shares in the last quarter. Geode Capital Management LLC boosted its stake in OptimizeRx by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 400,621 shares of the company's stock valued at $1,948,000 after purchasing an additional 4,821 shares in the last quarter. Wells Fargo & Company MN boosted its stake in OptimizeRx by 33.3% during the 4th quarter. Wells Fargo & Company MN now owns 11,208 shares of the company's stock valued at $54,000 after purchasing an additional 2,797 shares in the last quarter. Barclays PLC boosted its stake in OptimizeRx by 13.5% during the 4th quarter. Barclays PLC now owns 30,574 shares of the company's stock valued at $148,000 after purchasing an additional 3,640 shares in the last quarter. Finally, XTX Topco Ltd bought a new position in OptimizeRx during the 4th quarter valued at $178,000. 76.47% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on OPRX. Wall Street Zen raised OptimizeRx from a "hold" rating to a "buy" rating in a research note on Thursday, May 22nd. Roth Capital reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Friday, August 8th. Stifel Nicolaus increased their price target on OptimizeRx from $16.00 to $18.00 and gave the company a "buy" rating in a research note on Friday, August 8th. Citigroup reaffirmed an "outperform" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Finally, B. Riley reaffirmed a "buy" rating on shares of OptimizeRx in a research note on Tuesday, May 13th. Eight equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $11.81.

OptimizeRx Price Performance

Shares of NASDAQ:OPRX opened at $15.49 on Thursday. OptimizeRx Corp. has a one year low of $3.78 and a one year high of $18.22. The stock has a fifty day moving average of $13.89 and a 200-day moving average of $10.44. The company has a market capitalization of $287.65 million, a PE ratio of -28.68, a price-to-earnings-growth ratio of 5.27 and a beta of 1.33. The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.57 and a current ratio of 2.57.

OptimizeRx Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

Want to see what other hedge funds are holding OPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for OptimizeRx Corp. (NASDAQ:OPRX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.